EA200500757A1 - Новое применение декстрансульфата - Google Patents
Новое применение декстрансульфатаInfo
- Publication number
- EA200500757A1 EA200500757A1 EA200500757A EA200500757A EA200500757A1 EA 200500757 A1 EA200500757 A1 EA 200500757A1 EA 200500757 A EA200500757 A EA 200500757A EA 200500757 A EA200500757 A EA 200500757A EA 200500757 A1 EA200500757 A1 EA 200500757A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dextran sulfate
- ibmir
- medicament
- patients
- pharmaceutically acceptable
- Prior art date
Links
- 229960000633 dextran sulfate Drugs 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 241000282887 Suidae Species 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 230000000877 morphologic effect Effects 0.000 abstract 1
- 210000003240 portal vein Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Botany (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Настоящее изобретение относится к применению декстрансульфата или его фармацевтически приемлемого производного для изготовления лекарства для лечения немедленной воспалительной реакции, опосредованной кровью (IBMIR, instant blood-mediated inflammatory reaction). Кроме того, изобретение относится к применению декстрансульфата или его фармацевтически приемлемого производного для изготовления лекарства для лечения морфологического разрушения клеточных трансплантатов и отторжения клеточных трансплантатов, вызванных IBMIR. Данное изобретение можно применять для пациентов, страдающих диабетом 1 типа, которым в воротную вену трансплантируют островки Лангерганса свиньи. Введение декстрансульфата по изобретению подавляет и предотвращает отторжение и разрушение трансплантируемых островков и обеспечивает возможность нормогликемии у пациентов.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203526A SE525461C3 (sv) | 2002-11-28 | 2002-11-28 | Ny användning av dextransulfat |
PCT/SE2003/001830 WO2004047848A1 (en) | 2002-11-28 | 2003-11-26 | New use of dextran sulfate |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200500757A1 true EA200500757A1 (ru) | 2005-12-29 |
EA010409B1 EA010409B1 (ru) | 2008-08-29 |
Family
ID=20289705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500757A EA010409B1 (ru) | 2002-11-28 | 2003-11-26 | Применение декстрансульфата для ингибирования немедленной воспалительной реакции, опосредованной кровью |
Country Status (26)
Country | Link |
---|---|
US (5) | US8629123B2 (ru) |
EP (1) | EP1567171B1 (ru) |
JP (2) | JP4315908B2 (ru) |
KR (1) | KR100828807B1 (ru) |
CN (1) | CN1296051C (ru) |
AT (1) | ATE359798T1 (ru) |
AU (1) | AU2003302378B2 (ru) |
BR (1) | BRPI0316666B8 (ru) |
CA (1) | CA2507595C (ru) |
CY (1) | CY1106739T1 (ru) |
DE (1) | DE60313356T2 (ru) |
DK (1) | DK1567171T3 (ru) |
EA (1) | EA010409B1 (ru) |
ES (1) | ES2285270T3 (ru) |
HK (1) | HK1087042A1 (ru) |
HR (1) | HRP20050439B1 (ru) |
IL (1) | IL168626A (ru) |
IS (1) | IS2405B (ru) |
NO (1) | NO326946B1 (ru) |
NZ (1) | NZ540744A (ru) |
PL (1) | PL216067B1 (ru) |
PT (1) | PT1567171E (ru) |
SE (1) | SE525461C3 (ru) |
SI (1) | SI1567171T1 (ru) |
WO (1) | WO2004047848A1 (ru) |
ZA (1) | ZA200504111B (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007312880A1 (en) * | 2006-10-20 | 2008-04-24 | The Australian National University | Inhibition of degradation of extracellular matrix |
WO2008153962A2 (en) * | 2007-06-08 | 2008-12-18 | The Trustees Of The University Of Pennylvania | Method of reducing tissue loss in pancreatic islet cell transplantation |
WO2011109877A1 (en) * | 2010-03-12 | 2011-09-15 | The Australian National University | Heparan sulfate replacement therapy |
TR201910511T4 (tr) * | 2010-07-16 | 2019-08-21 | Tx Medic Ab | Hücre terapisi. |
CN102973592A (zh) * | 2012-11-26 | 2013-03-20 | 合肥博太医药生物技术发展有限公司 | 硫酸葡聚糖在制备治疗糖尿病药物中的应用 |
SE537742C2 (sv) | 2013-05-13 | 2015-10-13 | Tx Medic Ab | Dextransulfat för cellmobilisering |
GB201408233D0 (en) | 2014-05-09 | 2014-06-25 | Austrianova Singapore Pte Ltd | Use of polyanionic composition |
CA2951686C (en) * | 2014-06-12 | 2019-05-21 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenesis in a subject |
WO2015190989A1 (en) * | 2014-06-12 | 2015-12-17 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject |
SE538503C2 (en) | 2014-11-11 | 2016-08-16 | Tx Medic Ab | New dextran sulfate |
SE539575C2 (en) * | 2015-07-30 | 2017-10-17 | Tx Medic Ab | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
EP3678675A4 (en) * | 2017-09-08 | 2021-07-07 | TX Medic AB | NEW USE OF DEXTRAN SULFATE |
IL297275A (en) * | 2020-04-15 | 2022-12-01 | Tx Medic Ab | Treatment of corona virus infections |
SE544768C2 (en) * | 2021-03-24 | 2022-11-08 | Tx Medic Ab | Combination for treatment of thromboinflammation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0240098A3 (en) * | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo and polysaccharides for the treatment of diseases caused by retroviruses |
IL88554A0 (en) * | 1988-12-01 | 1989-07-31 | Hadassah Med Org | Compositions containing a compound binding to a heparin receptor |
TW318142B (ru) | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
US5464815A (en) | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
CN1178070A (zh) * | 1996-09-27 | 1998-04-08 | 刘春江 | 组织脏器移植用保存溶液·手术等时组织脏器保护溶液 |
CN1057192C (zh) * | 1997-09-10 | 2000-10-11 | 上海长征医院 | 一种配制多器官保存液的方法 |
-
2002
- 2002-11-28 SE SE0203526A patent/SE525461C3/sv not_active IP Right Cessation
-
2003
- 2003-11-26 EP EP03811973A patent/EP1567171B1/en not_active Expired - Lifetime
- 2003-11-26 US US10/535,876 patent/US8629123B2/en active Active
- 2003-11-26 NZ NZ540744A patent/NZ540744A/en not_active IP Right Cessation
- 2003-11-26 CN CNB2003801045438A patent/CN1296051C/zh not_active Expired - Lifetime
- 2003-11-26 SI SI200330809T patent/SI1567171T1/sl unknown
- 2003-11-26 EA EA200500757A patent/EA010409B1/ru not_active IP Right Cessation
- 2003-11-26 PT PT03811973T patent/PT1567171E/pt unknown
- 2003-11-26 ES ES03811973T patent/ES2285270T3/es not_active Expired - Lifetime
- 2003-11-26 DK DK03811973T patent/DK1567171T3/da active
- 2003-11-26 AU AU2003302378A patent/AU2003302378B2/en not_active Expired
- 2003-11-26 BR BRPI0316666A patent/BRPI0316666B8/pt active IP Right Grant
- 2003-11-26 AT AT03811973T patent/ATE359798T1/de active
- 2003-11-26 DE DE60313356T patent/DE60313356T2/de not_active Expired - Lifetime
- 2003-11-26 KR KR1020057009717A patent/KR100828807B1/ko active IP Right Grant
- 2003-11-26 PL PL376302A patent/PL216067B1/pl unknown
- 2003-11-26 JP JP2004555208A patent/JP4315908B2/ja not_active Expired - Lifetime
- 2003-11-26 CA CA2507595A patent/CA2507595C/en not_active Expired - Lifetime
- 2003-11-26 WO PCT/SE2003/001830 patent/WO2004047848A1/en active IP Right Grant
-
2005
- 2005-05-17 IL IL168626A patent/IL168626A/en active IP Right Grant
- 2005-05-17 HR HR20050439A patent/HRP20050439B1/xx not_active IP Right Cessation
- 2005-05-20 ZA ZA200504111A patent/ZA200504111B/en unknown
- 2005-05-25 NO NO20052505A patent/NO326946B1/no not_active IP Right Cessation
- 2005-06-23 IS IS7908A patent/IS2405B/is unknown
-
2006
- 2006-07-03 HK HK06107463A patent/HK1087042A1/xx not_active IP Right Cessation
-
2007
- 2007-07-17 CY CY20071100954T patent/CY1106739T1/el unknown
-
2009
- 2009-03-17 JP JP2009064780A patent/JP4972113B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-11 US US12/685,005 patent/US8906884B2/en active Active
-
2013
- 2013-12-06 US US14/099,518 patent/US8901104B2/en not_active Expired - Lifetime
- 2013-12-06 US US14/099,493 patent/US9364499B2/en not_active Expired - Fee Related
-
2016
- 2016-01-20 US US15/001,380 patent/US10307440B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200500757A1 (ru) | Новое применение декстрансульфата | |
Qian et al. | Radioprotective effect of hydrogen in cultured cells and mice | |
ES2169128T3 (es) | Procedimientos para el tratamiento de enfermedades utilizando celulas de sertoli y aloinjertos o xenoinjertos. | |
MA29346B1 (fr) | Formulations pharmaceutiques gastrorésistantes à base de rifaximine | |
RU2009107030A (ru) | Комбинированная терапия | |
TR200102977T2 (tr) | Yeni tedavi yöntemi. | |
US10548942B2 (en) | CXCR antagonistic peptides and uses thereof | |
EA200000058A1 (ru) | Лечение посредством блокады cd154 при трансплантации ткани панкреатических островков | |
CA2364451A1 (en) | Agent for treatment of arthritic disease | |
MX2008015392A (es) | Tratamiento de enfermedades isquemicas que usan eritropoyetina. | |
DE60115432D1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
Otsuka et al. | Nicotinamide and 3-aminobenzamide reduce interferon-γ-induced class II MHC (HLA-DR and-DP) molecule expression on cultured human endothelial cells and fibroblasts | |
Lehnert et al. | Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration. | |
DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
DK0883406T3 (da) | Anvendelse af IL-7 til behandling af autoimmune sygdomme og især insulinafhængig diabe-tesmellitus i særdeleshed | |
Manasia et al. | Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients. | |
Eldad et al. | Cyclosporin A treatment failed to extend skin allograft survival in two burn patients | |
SE8804640D0 (sv) | Medicament comprising cyclolinopeptide a | |
Wang et al. | Mesenchymal Stem Cell Therapy for Acetaminophen-related Liver Injury: A Systematic Review and Meta-analysis of Experimental Studies In Vivo | |
Acchiardo et al. | Ultrastructural changes in gentamicin nephrotoxicity | |
이기준 | Limb transplantation: indications and recent results | |
Lee | Relative potency factors derived from NOAELs for assessing cumulative risk of pesticides | |
RU2001120483A (ru) | Способ лечения больных нейросенсорной тугоухостью в остром периоде | |
Reddy et al. | Mycetoma of the Hand | |
RU2001132588A (ru) | Новое применение вещества для пнс |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TK4A | Corrections in published eurasian patents | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY |